IGFBP4

Across TCGA pan-cancer cohorts, IGFBP4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGFBP4 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher IGFBP4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGFBP4 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where IGFBP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.339	1.000	.003	17	view →
LUAD	OS	Quartile	II,III,IV	0.385	0.892	.012	16	view →
PDAC	DFS	Tertile	All	0.224	0.535	.008	15	view →
OV	DFS	Median	All	0.900	0.670	.015	8	view →
COAD	DFS	Median	All	0.887	1.000	.020	6	view →
LSCC	OS	Tertile	II,III,IV	0.907	1.000	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IGFBP4–CCRCC (OS)

Open the CCRCC breakdown →